Everest Group’s 2025 Life Sciences eCOA PEAK Matrix® Assessment highlights Medable eCOA leadership in ease of use, AI innovation, and patient-centered design

Medable Inc., a leading provider of clinical trial technology, today announced it has been named a Leader in Everest Group’s 2025 "Life Sciences Electronic Clinical Outcome Assessment (eCOA) Products PEAK Matrix® Assessment." Medable was recognized among 19 vendors for its strong performance across three key areas: buyer priorities, innovation, and future focus.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917914493/en/

Life Sciences Electronic Clinical Outcome Assessment (eCOA) Products PEAK Matrix® Assessment 2025 | Medable is positioned as a Leader

Medable was named a Leader for its continued investment in AI and machine learning to enhance platform efficiency, localization, real-time analytics, broad multimodal data capture, and strategic partnerships. Buyers highlighted Medable’s flexible and competitive pricing models. The platform supports multimodal data capture—including web, mobile, and bring-your-own-device—underscoring its technical maturity and adaptability.

The adoption of eCOA software is accelerating as clinical trials increasingly shift toward digital solutions. According to The Business Research Company, the eCOA and eSource market is experiencing significant growth, driven by the demand for improved data accuracy, regulatory compliance, and patient-centric trial designs.

“Medable is proud to be recognized for driving meaningful innovation in clinical research – particularly for this critical, sought-after technology,” said Dr. Michelle Longmire, CEO and co-founder of Medable. “This reflects our continued focus on building technology that simplifies trials, improves data quality, and keeps patients and sites at the center. We're committed to pushing the industry forward and driving toward our 1:1:1 vision.”

With the recent launch of Agent Studio, Medable continues to lead digital transformation in life sciences. Sponsors and CROs can now deploy AI-powered agents to address costly manual bottlenecks in development and close the “white space” of clinical trials, which accounts for 45% of total clinical development timeline.

Learn more about the growth of the eCOA market and the benefits cloud-based eCOA platforms bring to clinical trials here and about Medable’s AI-powered eCOA here.

About Medable

Medable is on a mission to get effective therapies to people faster. Its digital clinical trials platform enhances speed, scale, and patient access in clinical research, accelerating medicines for thousands of conditions without treatment or cure. Awarded Best Digital Health Solution by the Galien Foundation, Medable’s platform has been deployed in nearly 400 trials in 70 countries and 120 languages, serving more than one million patients globally. Medable is a privately held, venture-backed company headquartered in Palo Alto, California, and was listed for the second year in a row on the Inc. 5000 in 2024.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250917914493/en/

Medable was named a Leader for its continued investment in AI and machine learning to enhance platform efficiency, localization, real-time analytics, broad multimodal data capture, and strategic partnerships.